18. Spinocerebellar degeneration Clinical trials / Disease details
Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05573698 (ClinicalTrials.gov) | September 27, 2022 | 6/10/2022 | Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia | A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose and Multi-Dose Study of DT-216 in Adult Patients With Friedreich Ataxia | Friedreich Ataxia | Drug: DT-216;Drug: Placebo | Design Therapeutics | NULL | Recruiting | 18 Years | 55 Years | All | 38 | Phase 1 | United States |
| 2 | NCT05285540 (ClinicalTrials.gov) | March 11, 2022 | 9/3/2022 | Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia | A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia | Friedreich Ataxia | Drug: DT-216;Drug: DT-216 matching Placebo | Design Therapeutics | NULL | Recruiting | 18 Years | 55 Years | All | 25 | Phase 1 | United States |